Program
Tirzepatide
Also written as “Arm 5- Tirzepatide”, “Tirzepatide Dose 1” and “Tirzepatide Dose 2”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus, Type 1 · Psoriasis · Non-alcoholic Fatty Liver Disease, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 6918 open or running | phase 4since Jun 22, 2022 | Apr 29, 2016 | Nov 2026phase 1 · NCT07299084 |
| Florida Academic Centers Research and Education | 11 open or running | no phasesince Mar 1, 2024 | Mar 1, 2024 | none ahead |
| Hudson Biotech | 11 open or running | phase 3since Mar 8, 2026 | Mar 8, 2026 | Feb 14, 2027phase 3 · NCT07481747 |
| Lexaria Bioscience | 10 open or running | phase 1since Oct 16, 2024 | Oct 16, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 43 studies since May 15, 2019.
- Oct 4, 2024Phase 4 study in Diabetes Mellitus, Type 2Eli Lilly · NCT06635057 · 166 enrolled · Saudi Arabia, United Arab Emirates
- Oct 14, 2024Phase 2 study in ObesityEli Lilly · NCT06643728 · 252 enrolled · United States
- Oct 16, 2024Lexaria Bioscience's first study: phase 1 study in Type2diabetesNew to Lexaria BioscienceLexaria Bioscience · NCT06648031 · 148 enrolled · Australia
- Mar 3, 20252 phase 4 studiesEli Lilly · NCT06864026, NCT06857942
- Mar 24, 2025Phase 2 study in ObesityEli Lilly · NCT06901349 · United States, Argentina, Canada and more
- Apr 4, 20253 phase 3 studiesEli Lilly · NCT06914895, NCT06937099, NCT06937086
- May 6, 2025Phase 3 study in Diabetes Mellitus, Type 1Eli Lilly · NCT06962280 · 465 enrolled · United States, Argentina, Brazil and more
- Aug 28, 2025Phase 3 study in Non-alcoholic Fatty Liver DiseaseEli Lilly · NCT07165028 · 4,500 planned · United States, Argentina, Australia and more
- Nov 19, 2025Phase 4 study in ObesityEli Lilly · NCT07247084 · 3,000 planned · United Kingdom
- Dec 10, 2025Phase 1 study in Diabetes Mellitus, Type 2Eli Lilly · NCT07299084 · 40 enrolled · Singapore
- Feb 23, 2026Phase 4 study in Diabetes Mellitus, Type 2Eli Lilly · NCT07438444 · 344 enrolled · India
- Mar 8, 2026Hudson Biotech's first study: phase 3 study in ObesityNew to Hudson BiotechHudson Biotech · NCT07481747 · 2,539 planned · China
- Sep 1, 2026Phase 1 study in Diabetes Mellitus, Type 1Eli Lilly · NCT07803744 · 18 planned · United States
- Sep 9, 2026Phase 3 study in ObesityEli Lilly · NCT07817875 · 150 planned · United States, Belgium, Israel and more
Ahead
- Nov 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 2Eli Lilly · NCT07299084
- Nov 2026Primary completion: phase 3 study in Diabetes Mellitus, Type 1Eli Lilly · NCT06962280
- Nov 2026Primary completion: phase 3 study in Diabetes Mellitus, Type 1Eli Lilly · NCT06914895
- Dec 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 1Eli Lilly · NCT07803744
TargetBeta
“Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| olatorepatide | Hansoh Pharmaceutical Group | phase 3 | 12 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
| enicepatide | Hoffmann-La Roche | phase 3 | 10 |
| VK2735rule | Viking Therapeutics | phase 3 | 8 |
| NNC0519-0130 | Novo Nordisk | phase 2 | 11 |
| BI 3034701 | Boehringer Ingelheim | phase 2 | 6 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
| NA-931rule | biomed-industries-inc | phase 2 | 3 |
Studies
The newest 60 of 72 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07817875Obesity · United States, Belgium, Israel and more | 3 | Recruiting | Eli Lilly | Dec 2029 | 150 |
| NCT07803744Diabetes Mellitus, Type 1 · United States | 1 | Recruiting | Eli Lilly | Dec 2026 | 18 |
| NCT07481747Obesity · China | 3 | Recruiting | Hudson Biotech | Feb 14, 2027 | 2,539 |
| NCT07438444Diabetes Mellitus, Type 2 · India | 4 | Active, not recruiting | Eli Lilly | Jul 2027 | 344 |
| NCT07299084Diabetes Mellitus, Type 2 · Singapore | 1 | Active, not recruiting | Eli Lilly | Nov 2026 | 40 |
| NCT07247084Obesity · United Kingdom | 4 | Recruiting | Eli Lilly | Jul 2029 | 3,000 |
| NCT07165028Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 3 | Recruiting | Eli Lilly | Aug 2030 | 4,500 |
| NCT06962280Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Eli Lilly | Nov 2026 | 465 |
| NCT06937099Crohn Disease · United States, Austria, Belgium and more | 3 | Recruiting | Eli Lilly | May 2028 | 290 |
| NCT06937086Colitis, Ulcerative · United States, Austria, Belgium and more | 3 | Recruiting | Eli Lilly | Apr 2028 | 350 |
| NCT06914895Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Eli Lilly | Nov 2026 | 905 |
| NCT06901349Obesity · United States, Argentina, Canada and more | 2 | Withdrawn | Eli Lilly | Jun 10, 2025 | 0 |
| NCT06864026Arthritis, Psoriatic · United States, Puerto Rico | 4 | Active, not recruiting | Eli Lilly | Aug 2027 | 200 |
| NCT06857942Psoriasis · United States | 4 | Recruiting | Eli Lilly | May 2028 | 200 |
| NCT06648031Type2diabetes · Australia | 1 | Completed | Lexaria Bioscience | Jul 31, 2025 | 148 |
| NCT06643728Obesity · United States | 2 | Active, not recruiting | Eli Lilly | Jan 16, 2026 | 252 |
| NCT06635057Diabetes Mellitus, Type 2 · Saudi Arabia, United Arab Emirates | 4 | Completed | Eli Lilly | Apr 15, 2026 | 166 |
| NCT06588296Arthritis, Psoriatic · United States, Puerto Rico | 3 | Completed | Eli Lilly | Nov 18, 2025 | 279 |
| NCT06588283Psoriasis · United States, Puerto Rico | 3 | Completed | Eli Lilly | Jan 8, 2026 | 281 |
| NCT06439277Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Eli Lilly | Oct 2027 | 300 |
| NCT06301256Hidradenitis Suppurativa | – | Not yet recruiting | Florida Academic Centers Research and Education | Mar 11, 2025 | 20 |
| NCT06075667Obesity · United States, Canada, Czechia and more | 3 | Active, not recruiting | Eli Lilly | Jun 2, 2026 | 160 |
| NCT06047548Overweight · United States | 3 | Completed | Eli Lilly | Jan 20, 2026 | 441 |
| NCT06037252Diabetes Mellitus, Type 2 · United States, Argentina, Mexico and more | 2 | Active, not recruiting | Eli Lilly | Jan 8, 2026 | 414 |
| NCT05978713Healthy · United States | 1 | Completed | Eli Lilly | Mar 12, 2024 | 11 |
| NCT05963022Diabetes Mellitus, Type 2 · China | 3 | Completed | Eli Lilly | Oct 9, 2024 | 206 |
| NCT05810597Healthy · United States | 1 | Completed | Eli Lilly | Jul 17, 2023 | 65 |
| NCT05706506Diabetes Mellitus, Type 2 · United States | 4 | Completed | Eli Lilly | Oct 31, 2023 | 152 |
| NCT05696847Obesity · United States | 1 | Completed | Eli Lilly | Jan 16, 2025 | 28 |
| NCT05691712Diabetes Mellitus, Type 2 · China | 3 | Completed | Eli Lilly | Jul 1, 2024 | 257 |
| NCT05564039Diabetes Mellitus, Type 2 · United States, Belgium, Germany and more | 4 | Completed | Eli Lilly | Jul 15, 2024 | 282 |
| NCT05556512Obesity · United States, Argentina, Australia and more | 3 | Active, not recruiting | Eli Lilly | Oct 2027 | 15,374 |
| NCT05822830Obesity · United States, Puerto Rico | 3 | Completed | Eli Lilly | Nov 13, 2024 | 751 |
| NCT05536804Overweight · United States, Austria, Canada and more | 2 | Completed | Eli Lilly | Jul 6, 2026 | 134 |
| NCT05433584Diabetes Mellitus, Type 2 · United States, Argentina, Canada and more | 4 | Active, not recruiting | Eli Lilly | Oct 21, 2025 | 794 |
| NCT05412004Sleep Apnea, Obstructive · United States, Australia, Brazil and more | 3 | Completed | Eli Lilly | Mar 12, 2024 | 469 |
| NCT05260021Diabetes Mellitus · United States, Australia, Brazil and more | 3 | Completed | Eli Lilly | Jul 30, 2024 | 99 |
| NCT05024032Obesity · China | 3 | Completed | Eli Lilly | Dec 27, 2022 | 210 |
| NCT04844918Obesity · Japan | 3 | Completed | Eli Lilly | Jun 24, 2023 | 267 |
| NCT04847557Obesity · United States, Argentina, Brazil and more | 3 | Completed | Eli Lilly | Jul 2, 2024 | 731 |
| NCT04660643Obesity · United States, Argentina, Brazil and more | 3 | Completed | Eli Lilly | Apr 25, 2023 | 783 |
| NCT04657016Obesity · United States, Argentina, Brazil and more | 3 | Completed | Eli Lilly | Apr 20, 2023 | 579 |
| NCT04657003Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Completed | Eli Lilly | Mar 16, 2023 | 938 |
| NCT04537923Diabetes Mellitus, Type 2 · United States, Argentina, Belgium and more | 3 | Completed | Eli Lilly | Oct 11, 2022 | 1,428 |
| NCT04407234Overweight · United States | 1 | Completed | Eli Lilly | Jan 7, 2021 | 36 |
| NCT04311424Healthy · United Kingdom | 1 | Completed | Eli Lilly | Oct 2, 2020 | 6 |
| NCT04311411Obesity · United States | 1 | Completed | Eli Lilly | Dec 16, 2022 | 114 |
| NCT04255433Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jun 12, 2025 | 13,299 |
| NCT04235959Diabetes Mellitus, Type 2 · China | 1 | Completed | Eli Lilly | Aug 17, 2021 | 24 |
| NCT04184622Overweight · United States, Argentina, Brazil and more | 3 | Completed | Eli Lilly | Apr 1, 2022 | 2,539 |
| NCT04172987Healthy · United States | 1 | Completed | Eli Lilly | Feb 9, 2021 | 40 |
| NCT04166773Non-alcoholic Fatty Liver Disease · United States, Belgium, France and more | 2 | Completed | Eli Lilly | Dec 11, 2023 | 190 |
| NCT04093752Diabetes Mellitus, Type 2 · Australia, China, India and more | 3 | Completed | Eli Lilly | Nov 1, 2021 | 917 |
| NCT04081337Obesity · United States | 1 | Completed | Eli Lilly | May 26, 2022 | 55 |
| NCT04050670Healthy · United States | 1 | Completed | Eli Lilly | Apr 3, 2020 | 54 |
| NCT04050553Diabetes Mellitus, Type 2 · Austria | 1 | Completed | Eli Lilly | Jan 25, 2022 | 42 |
| NCT04039503Diabetes Mellitus, Type 2 · United States, Czechia, Germany and more | 3 | Completed | Eli Lilly | Dec 22, 2020 | 475 |
| NCT04004988Healthy · Singapore | 1 | Completed | Eli Lilly | Dec 16, 2019 | 47 |
| NCT03987919Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jan 28, 2021 | 1,879 |
| NCT03954834Diabetes Mellitus, Type 2 · United States, India, Japan and more | 3 | Completed | Eli Lilly | Oct 5, 2020 | 478 |
How it is read
Names in the registry
- “Tirzepatide”, 69 entries
- “Arm 5- Tirzepatide”, 1 entry
- “Tirzepatide Dose 1”, 1 entry
- “Tirzepatide Dose 2”, 1 entry
- “TIRZEPATIDE”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 29 studies
- Obesity, 21 studies
- Diabetes Mellitus, Type 1, 3 studies
- Psoriasis, 2 studies
- Non-alcoholic Fatty Liver Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.